The diagnostic utility and reference intervals for blood studies in Aldabra giant tortoises (Aldabrachelys gigantea) are not well described. Capillary zone electrophoresis (CZE) has been evaluated in non-mammalian vertebrates and shows a higher fraction resolution and less overall variation in results than agarose gel electrophoresis. To date, the investigation of novel biomarkers has been limited in reptiles. MRP-126, a calgranulin homologue in reptiles, has not been evaluated for its diagnostic potential in tortoises. The goals of this study were to establish preliminary reference intervals for CZE protein electrophoresis and to examine MRP-126 as a potential biomarker of inflammation in Aldabra giant tortoises. In 27 clinically healthy tortoises, CZE resolved seven protein fractions. In tortoises with an inflammatory or infectious disease process (n = 4), MRP-126 concentrations and CZE fractions did not consistently increase or were abnormal. To strengthen the understanding of the diagnostic value of CZE and MRP-126 concentration in this species, future studies should evaluate a larger sample set inclusive of repeated measures of clinically abnormal tortoises as well as CZE and MRP-126 variations in regard to additional health conditions, age, sex, season, and geographic location.

A recombinant vaccine for rabbit hemorrhagic disease virus 2, a highly pathogenic virus, was granted emergency use authorization in the United States after the detection and spread of the virus starting in 2018. The goal of the current study was to assess pet rabbits (n = 29) through physical examination and routine clinical pathology testing using repeated assessments post-vaccination. In addition, seroconversion was also monitored after the initial vaccination and booster vaccination. Neither owners nor clinicians detected any physical abnormalities in relationship to the vaccine protocol. Hematological and clinical biochemistry testing showed some changes although median values were within species specific reference intervals. A significant increase in antibody levels was observed at day 21 (post-initial vaccination) and day 49 (post-booster vaccination) versus that present at baseline (p < 0.0001). However, variability in study rabbits was noted with some individuals showing low antibody levels as well as a lower overall response in older rabbits (r = −0.56, p = 0.006). A second cohort of rabbits was assessed at 11–12 months post-initial vaccination. In this second group, antibody levels were not significantly different from baseline levels (p = 0.21). Additional studies should be conducted to further define the variability in seroconversion and the term of protection in pet rabbits as the industry moves forward in the optimization of RHDV2 vaccines.